2018 Drug Development Pharmaceutical Companies 
European Pharmaceutical Review
AUGUST 1, 2022
The DDiCT project will be co-led by Bristol Myers Squibb (BMS)’s Disability Advancement Workplace Network (DAWN) and the Global Drug Development Team. The goal is to “ensure all patient groups are reflective of the real-world population and aligned with the epidemiology of the disease studies,” a statement said.
European Pharmaceutical Review
FEBRUARY 21, 2023
After the substance became legal in the UK in 2018, pharmaceutical companies have faced numerous obstacles to attain a fairer position in the industry. There is a clear framework in place now, and as a pharmaceutical company, we are certainly not looking to the MHRA to loosen or change any of the guidelines.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
DECEMBER 6, 2022
HPAPIs may now represent more than 30% of the drug development pipeline. Within that figure, GlobalData estimates that around 60% of pipeline HPAPIs are developed to target oncology. Many companies are now prioritising investments in containment systems, GlobalData research shows.
European Pharmaceutical Review
SEPTEMBER 21, 2023
In this Q&A, Karen Pinachyan, Head of Medical Affairs Europe at CSL Behring summarises key considerations for gene therapy drug development and the ideal approach for alleviating economic strain when advancing these modern treatments. 4,5 What is the key consideration drug developers should apply to gene therapies?
Pharma Marketing Network
MAY 15, 2023
Big data has become an increasingly important tool for businesses across various industries, and the pharmaceutical industry is no exception. However, the use of big data in pharmaceutical marketing also poses significant challenges that must be considered. Another challenge is the sheer volume of data that companies must manage.
Pharma Marketing Network
MARCH 23, 2023
Big data has become an increasingly important tool for businesses across various industries, and the pharmaceutical industry is no exception. However, the use of big data in pharmaceutical marketing also poses significant challenges that must be considered. Another challenge is the sheer volume of data that companies must manage.
pharmaphorum
AUGUST 31, 2021
However, like many other emerging healthcare technologies, they have been slow to gain traction and there is still confusion and scepticism around ECAs, stemming from a lack of precedence, step-by-step guidance and data to quantify their impact on drug development costs and clinical outcomes.
Expert insights. Personalized for you.
122 
Let's personalize your content